Impact of enzalutamide, an androgen receptor (AR) signalling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study
Titel:
Impact of enzalutamide, an androgen receptor (AR) signalling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study
Auteur:
Loriot, Y. Fizazi, K. Saad, F. Sternberg, C. Miller, K. Mulders, P. Chi, K. Hirmand, M. Selby, B. De Bono, J.